• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CG Oncology Stock In Focus After Earnings Report Shows Wider Losses

    Simply Wall St·11/14/2026 00:53:16
    Listen to the news
    • CG Oncology reported third quarter 2026 revenue of US$1.6 million and a net loss of US$56.89 million, with a basic loss per share from continuing operations of US$0.64, all relating to the period ended September 30, 2026.
    • Over the first nine months of 2026, CG Oncology recorded US$3.84 million in revenue and a widening net loss of US$196.15 million. This reflects the cash-intensive reality of advancing cretostimogene through late-stage development and early commercial preparation.
    • Next, the focus will be on how CG Oncology's larger nine-month loss and modest revenue base fit into its investment narrative.

    Scan beyond CG Oncology and compare this cash-intensive biotech story with other high-potential healthcare and research plays screened as 36 healthcare AI stocks.

    CG Oncology Investment Narrative Recap

    To own CG Oncology, you need to believe cretostimogene can progress through late stage trials and into broader non muscle invasive bladder cancer use while the current cash burn stays manageable. The latest quarter reinforces that this is still an R&D heavy story. Revenue of US$1.6 million is small next to a quarterly loss of US$56.89 million.

    The analyst consensus Narrative on Simply Wall St highlights expansion into BCG exposed and intermediate risk NMIBC and a lean commercial build as key near term levers. The larger nine month loss, at US$196.15 million, keeps execution risk around operating efficiency front and center but does not obviously change the next regulatory or trial milestone itself.

    The fresh earnings release is the disclosure that matters most right now. It updates investors on how quickly CG Oncology is spending to advance cretostimogene and set up commercialization, and it shows that losses have widened versus the prior year both in the quarter and year to date while revenue remains modest.

    This context matters for the catalysts in the analyst consensus Narrative on Simply Wall St. Plans to fund Phase 3 programs, manufacturing scale up and a targeted urology sales footprint lean heavily on that reported cash runway to 2029. The growing loss line is a reminder that if operating efficiency lags or pricing comes under pressure, the risk side of the thesis can move into focus quickly.

    CG Oncology's narrative projects US$658.8 million revenue and US$85.1 million earnings by 2029. Analysts are assuming revenue will grow at a very large 372.9% yearly rate and earnings would need to rise by about US$309.5 million from current earnings of a US$224.4 million loss to reach that forecast level.

    Uncover why CG Oncology's fair value indicates a 22% potential upside to its current price before the market adjusts to close that gap.

    NasdaqGS:CGON 1-Year Stock Price Chart
    NasdaqGS:CGON 1-Year Stock Price Chart

    Exploring Other Perspectives

    Three fair value views from the Simply Wall St Community span roughly US$91 to about US$488, so you are looking at a wide spread for CG Oncology. That diversity reflects very different expectations around pricing pressure, execution on cretostimogene trials, and the impact of widening losses on long term performance. Explore the full set of opinions before leaning on a single narrative.

    Explore 2 other CG Oncology fair value estimates, including one that suggests potential upside of up to 556% from the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider your own analysis and judgement.

    Looking For More Investment Ideas Beyond CG Oncology?

    If the CG Oncology story has sharpened your thinking about risk, reward, and timing, use that same lens on a broader watchlist. The Simply Wall St Screener lets you filter for different types of opportunities so you can build a line up that fits your own return and risk preferences.